1. Lazzeroni D, Coruzzi P. Risk stratification in secondary cardiovascular prevention. Minerva Cardioangiol. 2018;66(4):471-6. doi:10.23736/S0026-4725.18.04648-0.
2. Boitsov SA, Pogosova NV, Bubnova MG, et al. Cardiovascular prevention 2017. National guidelines. Russ J Cardiol. 2018;23(6):7-122. (In Russ.) Бойцов С.А., Погосова Н.В., Бубнова М.Г. и др. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации. Российский кардиологический журнал. 2018;23(6):7-122. doi:10.15829/1560-4071-2018-6-7-122.
3. Annemans L, Packard CJ, Briggs A, Ray KK. 'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. Eur Heart J. 2018;39(27):2546-50. doi:10.1093/eurheartj/ehx710.
4. Kontsevaya AV, Mukaneeva DK, Myrzamatova AO, et al. Economic damage of risk factors associated with morbidity and mortality from major chronic non-communicable diseases in Russia in 2016. Cardiovascular Therapy and Prevention. 2020;19(1):48-55. (In Russ.) Концевая А.В., Муканеева Д.К., Мырзаматова А.О. и др. Экономический ущерб факторов риска, обусловленный их вкладом в заболеваемость и смертность от основных хронических неинфекционных заболеваний в российской федерации в 2016 году. Кардиоваскулярная терапия и профилактика. 2020;19(1):48-55. doi:10.15829/1728-8800-2020-1-2396.
5. Kukharchuk VV, Ezhov MV, Sergienko IV, et al. Diagnostics and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations. VII revision. Atherosclerosis and dyslipidemia. 2020;1(38):7-40. (In Russ.) Кухарчук В.В., Ежов М.В., Сергиенко И.В. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. VII пересмотр. Атеросклероз и дислипидемии. 2020;1(38):7-40. doi:10.34687/2219-8202.JAD.2020.01.0002.
6. Blankstein R, Chandrashekhar Y. Extensive Coronary Artery Calcifications: No Longer Primary Prevention! JACC Cardiovasc Imaging. 2020;13:183-185. doi:10.1016/j.jcmg.2019.12.007.
7. Bonaca MP. Polyvascular disease and risk: When two is not better than one. Vasc Med. 2018;23(6):531-3. doi:10.1177/1358863X18796936.
8. Gutierrez JA, Mulder H, Jones WS, et al. Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID Trial. JAMA Netw Open. 2018;1(7):e185239. doi:10.1001/jamanetworkopen.2018.5239.
9. Zhang Q, Wang A, Zhang S, et al. Asymptomatic polyvascular disease and the risks of cardiovascular events and all-cause death. Atherosclerosis. 2017;262:1-7. doi:10.1016/j.atherosclerosis.2017.04.015.
10. Barbarash OL, Kashtalap VV. A patient with сoronary artery disease and multifocal atherosclerosis. how to optimize the prognosis? Medical advice. 2018;(16):32-8. (In Russ.) Пациент с ишемической болезнью сердца и мультифокальным атеросклерозом. Как оптимизировать прогноз? Медицинский совет. 2018;(16):32-8. doi:10.21518/2079-701X-2018-16-32-38.
11. Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763-816. doi:10.1093/eurheartj/ehx095.
12. Mach F, Baigent C, Catapano AL, et al.; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88. doi:10.1093/eurheartj/ehz455.
13. Sprynger M, Rigo F, Moonen M, et al.; EACVI Scientific Documents Committee. Focus on echovascular imaging assessment of arterial disease: complement to the ESC guidelines (PARTIM 1) in collaboration with the Working Group on Aorta and Peripheral Vascular Diseases. Eur Heart J Cardiovasc Imaging. 2018;19(11):1195-221. doi:10.1093/ehjci/jey103.
14. Rossello X, Bueno H, Pocock SJ, et al. Predictors of allcause mortality and ischemic events within and beyond 1 year after an acute coronary syndrome: results from the EPICOR registry. Clin Cardiol. 2019;42:111-9. doi:10.1002/clc.23116.
15. Rossello X, Dorresteijn JA, Janssen A, et al. Risk prediction tools in cardiovascular disease prevention: A report from the ESC Prevention of CVD Programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP). Eur J Prev Cardiol. 2019;26(14):1534-44. doi:10.1177/2047487319846715.
16. Calais F, Eriksson Östman M, Hedberg P, et al. Incremental prognostic value of coronary and systemic atherosclerosis after myocardial infarction. Int J Cardiol. 2018;261:6-11. doi:10.1016/j.ijcard.2018.02.035.
17. Eriksson Östman M, Calais F, Rosenblad A, et al. Prognostic impact of subclinical or manifest extracoronary artery diseases after acute myocardial infarction. Atherosclerosis. 2017;263:53-9. doi:10.1016/j.atherosclerosis.2017.05.027.
18. Miao B, Hernandez AV, Alberts MJ, et al. Incidence and Predictors of Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Disease or Multiple Risk Factors. J Am Heart Assoc. 2020;9(2):e014402. doi:10.1161/JAHA.119.014402.
19. Ershova AI, Boytsov SA, Drapkina OM, Balakhonova TV. Ultrasound markers of premanifest atherosclerosis of carotid and femoral arteries in assessment of cardiovascular risk. Russ J Cardiol. 2018;23(8):92-8. (In Russ.) Ершова А.И., Бойцов С.А., Драпкина О.М., Балахонова Т.В. Ультразвуковые маркеры доклинического атеросклероза сонных и бедренных артерий в оценке сердечно-сосудистого риска. Российский кардиологический журнал. 2018;23(8):92-8. doi:10.15829/1560-4071-2018-8-92-98.
20. Ershova AI, Balakhonova TV, Ivanova AA, et al. The problem of cardiovascular risk stratification depending on the severity of carotid and femoral artery atherosclerosis. Cardiovascular Therapy and Prevention. 2020;19(2):75-81. (In Russ.) Ершова А.И., Балахонова Т.В., Иванова А.А. и др. Проблема стратификации сердечно-сосудистого риска в зависимости от выраженности атеросклероза сонных и бедренных артерий. Кардиоваскулярная терапия и профилактика. 2020;19(2):75-81. doi:10.15829/1728-8800-2020-2441.
21. Genkel VV, Kuznetsova AS, Sumerkina VS, et al. The prognostic value of various carotid ultrasound parameters in patients at high and very high cardiovascular risk. Int J Cardiol. 2019;292:225-9. doi:10.1016/j.ijcard.2019.06.038.
22. Ihle-Hansen H, Vigen T, Ihle-Hansen H, et al. Prevalence of Carotid Plaque in a 63- to 65-Year-Old Norwegian Cohort From the General Population: The ACE (Akershus Cardiac Examination) 1950 Study. J Am Heart Assoc. 2018;7(10):e008562. doi:10.1161/JAHA.118.008562.
23. Genkel VV, Salashenko AO, Shamaeva TN, et al. Atherosclerosis of peripheral arteries in patients with coronary artery disease and type 2 diabetes mellitus. Therapeutic archive. 2019;91(10):54-62. (In Russ.) Генкель В.В., Салашенко А.О., Шамаева Т.Н. и др. Атеросклероз периферических артерий у пациентов с ишемической болезнью сердца и сахарным диабетом 2-го типа. Терапевтический архив. 2019;91(10):54-62. doi:10.26442/00403660.2019.10.000106.
24. Zhao Y, Evans MA, Allison MA, et al. Multisite atherosclerosis in subjects with metabolic syndrome and diabetes and relation to cardiovascular events: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2019;282:202-9. doi:10.1016/j.atherosclerosis.2018.12.005.
25. Verma S, Mazer CD, Bhatt DL. The perils of polyvascular disease in type 2 diabetes. Lancet Diabetes Endocrinol. 2018;6(12):914-6. doi:10.1016/S2213-8587(18)30311-5.